11 results on '"Alikhanov, B"'
Search Results
2. Efficiency and Tolerability of Artrofoon (Ultralow Doses and Antibodies to TNF-α) in Osteoarthrosis
- Author
-
Alikhanov, B. A. and Pavlenko, A. Yu.
- Published
- 2009
- Full Text
- View/download PDF
3. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis
- Author
-
Sands BE1, Peyrin-Biroulet L1, Loftus EV Jr1, Danese S1, Colombel JF1, Törüner M1, Jonaitis L1, Abhyankar B1, Chen J1, Rogers R1, Lirio RA1, Bornstein JD1, Schreiber S1, Calvo S, Gimenez E, Resk JH, Tron EP, Al-Ansari M, Andrews J, Bampton P, Debinski H, Hendy P, Holtmann G, Leong R, Moore G, Hindryckx P, Barac T, Draganova R, Kotzev I, Marinova I, Markov M, Mihaylov Y, Pavlov D, Penkova M, Petrov A, Spassova Z, Stoyanova D, Velev E, Vladimirov B, Yanev F, Axler J, Fedorak R, Fowler S Jr, Halder S, Jairath V, Ponich T, Wong K, Baez E, Ricardo J, Velasquez M, Banic M, Bogadi I, Borzan V, Zgrablic JC, Duvnjak M, Gusej M, Krznaric Z, Cechova I, Hala T, Janu L, Kohout P, Lukas M, Machkova M, Matous J, Ulbrych J, Vanasek T, Klinge L, Rannem T, Theede K, Borissova J, Kull K, Amil M, Bouhnik Y, Gilleta C, Fumery M, Grimaud JC, Hebuterne X, Laharie D, Moreau J, Peyrin-Biroulet L, Roblin X, Baumgart D, Buening C, Dinter J, Gauss A, Kuehbacher T, Fareed Rahman K, Schiefke I, Schreiber S, Von Amim U, Zeuzem S, Leung WK, Kin Kong Li M, Altorjay I, Bene L, Lakatos P, Molnar T, Salamon A, Schnabel R, Tulassay Z, Avni Y, Barkay O, Fishman S, Goldin E, Keret D, Lahat-Zok A, Melzer E, Naftali T, Nimer A, Ovadia B, Zittan E, Andriulli A, Cappello M, Castiglione F, Danese S, Fries W, Gionchetti P, Kohn A, Maconi G, Santino M, Savarino E, Privitera A, Romano M, Vecchi M, Villa E, Cheon JH, Han DS, Jang BI, Jeen YT, Kim JS, Kim SK, Kim HJ, Kim Y, Lee KM, Lee BI, Park DI, Park YS, Song GA, Ye BD, Pokrotnieks J, Tolmanis I, Denapiene G, Kancauskas A, Jakovlevaite V, Jonaitis L, Cruz Palacios A, Larriva de Los Reyes E, Asela Lujano Nicolas L, Mendoza Fuerte E, D'Haens G, Pierik M, Van Der Woude J, Adrych K, Danilkiewicz WC, Gawdis-Wojnarska B, Hartleb M, Karczewski M, Kierkus J, Malecka-Panas E, Petryka R, Piotrowski W, Regula J, Romatowski J, Rozciecha J, Rydzewska G, Smolinski P, Walczak P, Walczak M, Wozniak-Stolarska B, Cotter J, Lopes L, Portela F, Rodrigues Carvalho J, Simona Gheorghe L, Goldis AE, Mateescu RB, Abdulkhakov R, Agafyina A, Alexeeva O, Alikhanov B, Bunkova E, Dvorkin M, Gubonina I, Kashnikov V, Livzan M, Osipenko M, Parfenov A, Pershko A, Pesegova M, Rafalskiy V, Reshetko O, Simanenkov V, Tsybulko S, Valuyskikh E, Yakovlev A, Cvetkovic M, Damjanov D, Djuranovic S, Dugalic P, Nagorni A, Svorcan P, Zdravkovic Petrovic N, Bunganic I, Gregus M, Hlavaty T, Horvath F, Domenech Morral E, Jover Martinez R, Mendoza MIV, Shieh MJ, Wei CC, Altintas E, Atug O, Gonen C, Hamzaoglu H, Hulagu S, Toruner M, Chopey I, Danyliuk S, Datsenko O, Golovchenko N, Golovchenko O, Hospodarskyy I, Ivanov V, Klymenko V, Levchenko O, Lizogub V, Mostovoy Y, Oliinyk O, Polianskyi I, Pyrohovskyi V, Shevchuk S, Ursol G, Vdovychenko V, Vyshyvanyuk V, Beales I, Brookes M, Nwokolo C, Winter J, Aggarwal A, Aguilar H, Alnoah Z, Arce-Nunez E, Arimie C, Arterburn J, Baum C, Bellaguarda E, Bock B, Boone T, Callahan N, Chapman J, Chen S, Chiorean M, Coates A, Connor M, Dellon S, Dryden G, Du Vall G, Flores L, Fogel R, Frias J, Ginsburg P, Greenberg E, Grunkemeier D, Hellstern P, Herfarth H, Hoffman B, Horst S, Idarraga S, Iskandar H, Jain R, Jenkins E, Kaufman B, Khaleq A, Khan A, Khurana S, Lake J, Leavitt J, Leman B, Lewis D, Lindenberg D, Loftus EV, Korman L, Martin J, McCullough M, McNair A, Mehta N, Mutlu E, Narayen V, Paoli-Bruno J, Perez N, Phillips R, Raijman I, Ramirez-Vega R, Randall C, Rinesmith S, Ritter T, Safdi A, Saltzman M, Sands B, Seminerio J, Schulman M, Sedghi S, Shafran I, Shankar M, Silvers D, Soloman N, Tatum H, Tepper R, Tiongco F, Valdes M, Weber J, Zhang C., Sands, Be1, Peyrin-Biroulet, L1, Loftus EV, Jr1, Danese, S1, Colombel, Jf1, Törüner, M1, Jonaitis, L1, Abhyankar, B1, Chen, J1, Rogers, R1, Lirio, Ra1, Bornstein, Jd1, Schreiber, S1, Calvo, S, Gimenez, E, Resk, Jh, Tron, Ep, Al-Ansari, M, Andrews, J, Bampton, P, Debinski, H, Hendy, P, Holtmann, G, Leong, R, Moore, G, Hindryckx, P, Barac, T, Draganova, R, Kotzev, I, Marinova, I, Markov, M, Mihaylov, Y, Pavlov, D, Penkova, M, Petrov, A, Spassova, Z, Stoyanova, D, Velev, E, Vladimirov, B, Yanev, F, Axler, J, Fedorak, R, Fowler, S Jr, Halder, S, Jairath, V, Ponich, T, Wong, K, Baez, E, Ricardo, J, Velasquez, M, Banic, M, Bogadi, I, Borzan, V, Zgrablic, Jc, Duvnjak, M, Gusej, M, Krznaric, Z, Cechova, I, Hala, T, Janu, L, Kohout, P, Lukas, M, Machkova, M, Matous, J, Ulbrych, J, Vanasek, T, Klinge, L, Rannem, T, Theede, K, Borissova, J, Kull, K, Amil, M, Bouhnik, Y, Gilleta, C, Fumery, M, Grimaud, Jc, Hebuterne, X, Laharie, D, Moreau, J, Peyrin-Biroulet, L, Roblin, X, Baumgart, D, Buening, C, Dinter, J, Gauss, A, Kuehbacher, T, Fareed Rahman, K, Schiefke, I, Schreiber, S, Von Amim, U, Zeuzem, S, Leung, Wk, Kin Kong Li, M, Altorjay, I, Bene, L, Lakatos, P, Molnar, T, Salamon, A, Schnabel, R, Tulassay, Z, Avni, Y, Barkay, O, Fishman, S, Goldin, E, Keret, D, Lahat-Zok, A, Melzer, E, Naftali, T, Nimer, A, Ovadia, B, Zittan, E, Andriulli, A, Cappello, M, Castiglione, F, Danese, S, Fries, W, Gionchetti, P, Kohn, A, Maconi, G, Santino, M, Savarino, E, Privitera, A, Romano, M, Vecchi, M, Villa, E, Cheon, Jh, Han, D, Jang, Bi, Jeen, Yt, Kim, J, Kim, Sk, Kim, Hj, Kim, Y, Lee, Km, Lee, Bi, Park, Di, Park, Y, Song, Ga, Ye, Bd, Pokrotnieks, J, Tolmanis, I, Denapiene, G, Kancauskas, A, Jakovlevaite, V, Jonaitis, L, Cruz Palacios, A, Larriva de Los Reyes, E, Asela Lujano Nicolas, L, Mendoza Fuerte, E, D'Haens, G, Pierik, M, Van Der Woude, J, Adrych, K, Danilkiewicz, Wc, Gawdis-Wojnarska, B, Hartleb, M, Karczewski, M, Kierkus, J, Malecka-Panas, E, Petryka, R, Piotrowski, W, Regula, J, Romatowski, J, Rozciecha, J, Rydzewska, G, Smolinski, P, Walczak, P, Walczak, M, Wozniak-Stolarska, B, Cotter, J, Lopes, L, Portela, F, Rodrigues Carvalho, J, Simona Gheorghe, L, Goldis, Ae, Mateescu, Rb, Abdulkhakov, R, Agafyina, A, Alexeeva, O, Alikhanov, B, Bunkova, E, Dvorkin, M, Gubonina, I, Kashnikov, V, Livzan, M, Osipenko, M, Parfenov, A, Pershko, A, Pesegova, M, Rafalskiy, V, Reshetko, O, Simanenkov, V, Tsybulko, S, Valuyskikh, E, Yakovlev, A, Cvetkovic, M, Damjanov, D, Djuranovic, S, Dugalic, P, Nagorni, A, Svorcan, P, Zdravkovic Petrovic, N, Bunganic, I, Gregus, M, Hlavaty, T, Horvath, F, Domenech Morral, E, Jover Martinez, R, Mendoza, Miv, Shieh, Mj, Wei, Cc, Altintas, E, Atug, O, Gonen, C, Hamzaoglu, H, Hulagu, S, Toruner, M, Chopey, I, Danyliuk, S, Datsenko, O, Golovchenko, N, Golovchenko, O, Hospodarskyy, I, Ivanov, V, Klymenko, V, Levchenko, O, Lizogub, V, Mostovoy, Y, Oliinyk, O, Polianskyi, I, Pyrohovskyi, V, Shevchuk, S, Ursol, G, Vdovychenko, V, Vyshyvanyuk, V, Beales, I, Brookes, M, Nwokolo, C, Winter, J, Aggarwal, A, Aguilar, H, Alnoah, Z, Arce-Nunez, E, Arimie, C, Arterburn, J, Baum, C, Bellaguarda, E, Bock, B, Boone, T, Callahan, N, Chapman, J, Chen, S, Chiorean, M, Coates, A, Connor, M, Dellon, S, Dryden, G, Du Vall, G, Flores, L, Fogel, R, Frias, J, Ginsburg, P, Greenberg, E, Grunkemeier, D, Hellstern, P, Herfarth, H, Hoffman, B, Horst, S, Idarraga, S, Iskandar, H, Jain, R, Jenkins, E, Kaufman, B, Khaleq, A, Khan, A, Khurana, S, Lake, J, Leavitt, J, Leman, B, Lewis, D, Lindenberg, D, Loftus, Ev, Korman, L, Martin, J, Mccullough, M, Mcnair, A, Mehta, N, Mutlu, E, Narayen, V, Paoli-Bruno, J, Perez, N, Phillips, R, Raijman, I, Ramirez-Vega, R, Randall, C, Rinesmith, S, Ritter, T, Safdi, A, Saltzman, M, Sands, B, Seminerio, J, Schulman, M, Sedghi, S, Shafran, I, Shankar, M, Silvers, D, Soloman, N, Tatum, H, Tepper, R, Tiongco, F, Valdes, M, Weber, J, and Zhang, C.
- Published
- 2019
4. Land cover change in Tashkent province during 1992 – 2018
- Author
-
Alikhanov, B, primary, Alikhanova, Sh, additional, Oymatov, R, additional, Fayzullaev, Z, additional, and Pulatov, A, additional
- Published
- 2020
- Full Text
- View/download PDF
5. Assessment of land degradation changes in mountain areas in Tashkent province
- Author
-
Pulatov, B, primary, Umarova, Sh, additional, and Alikhanov, B, additional
- Published
- 2020
- Full Text
- View/download PDF
6. Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis
- Author
-
Sands, B. E., Sandborn, W. J., Panaccione, R., O'Brien, C. D., Zhang, H., Johanns, J., Adedokun, O. J., Li, K., Peyrin-Biroulet, L., Van Assche, G., Danese, S., Targan, S., Abreu, M. T., Hisamatsu, T., Szapary, P., Brown S, Marano C., Connor, S, De Cruz, P, Ding, Nj, Florin, T, Hendy, P, Leong, R, Moore, G, Pavli, P, Sparrow, M, Gassner, S, Vogelsang, H, Baert, F, Colard, A, De Vos, M, D'Heygere, F, Ferrante, M, Louis, E, Staessen, D, Berova, T, Churchev, J, Draganova, R, Gancheva, D, Ivanova, N, Marinova, I, Markov, M, Nikolov, R, Tsonev, N, Vassileva, G, Afif, W, Berstein, C, Bressler, B, Jairath, V, Lachance, Jr, Singh, R, Tilbe, K, Komarek, V, Kozeluhova, J, Lukas, M, Volfova, M, Dahlerup, J, Altwegg, R, Beorchia, S, Bouguen, G, Cadiot, G, Dupas, Jl, Desreumaux, P, Flourie, B, Grimaud, Jc, Guillaud, O, Moreau, J, Roblin, X, Zerbib, F, Baumgart, D, Beckebaum, S, Bokemeyer, B, Ebert, M, Hasselblatt, P, Lügering, A, Maaser, C, Schiefke, I, Schreiber, S, Seidler, U, Altorjay, I, Kiss, Gg, Literati-Nagy, B, Patai, A, Pecsi, G, Salamon, A, Schnabel, R, Székely, A, Tulassay, Z, Varga, M, Fich, A, Fishman, S, Konikoff, F, Lichtenstein, L, Rainis, T, Sbeit, W, Schwartz, D, Annese, V, Biancone, L, Bossa, F, Costintino, R, Danese, S, Fries, W, Gasbarrini, A, Guidi, L, Kohn, A, Maconi, G, Rocca, R, Rogai, F, Villa, E, Zoli, G, Akiho, H, Aoyama, N, Arisawa, T, Hidaka, H, Hisamatsu, T, Horiki, N, Inaba, T, Inoue, S, Ishida, T, Ishida, H, Ishiguro, Y, Ishihara, S, Iwabuchi, M, Kato, J, Katsushima, S, Kobayashi, T, Kojima, Y, Kurihara, H, Masuo, T, Matsui, T, Matsumoto, T, Matsuoka, K, Mitsuyama, K, Motoya, S, Nakagawa, T, Nakai, K, Nakamura, S, Niihara, T, Ohnishi, Y, Ohta, A, Osada, T, Ryuichi, I, Sakai, Y, Sakata, Y, Sameshima, Y, Sano, K, Shibatoge, M, Shibuya, T, Suzuki, Y, Takeshima, F, Tanaka, S, Taruishi, M, Tokito, S, Ueo, T, Watanabe, K, Yamagami, H, Cheon, Jh, Cho, Kb, Knowles, Kim, Kim, Hj, Kim, Y, Lee, Km, Yang, Sk, D'Haens, G, Pierik, M, Gearry, R, Inns, S, Rowbotham, D, Schultz, M, Bochenek, A, Gawdis-Wojnarska, B, Kleczkowski, D, Leszczyszyn, J, Malecka-Panas, E, Mamos, A, Petryka, R, Regula, J, Rozciecha, J, Stefanuik, P, Wozniak-Stolarska, B, Cimpoeru, N, Craciun, E, Ovidiu, Cf, Goldis, E, Ionita-Radu, F, Lazar, D, Suciu, I, Abdulkhakov, R, Alikhanov, B, Apartsin, K, Bakulin, I, Belousova, E, Gofman, A, Grinevich, V, Kulyapin, A, Nizov, A, Osipenko, M, Simanenkov, V, Tkachev, A, Uspenskiy, Y, Valuyskikh, E, Jovanovic, I, Nagorni, A, Svorcan, P, Zdravkovic, N, Bunganic, I, Abrahamovych, O, Bilianskyi, L, Datsenko, O, Golovchenko, O, Kharchenko, N, Klymenko, V, Levchenko, O, Lozynskyy, Y, Murenets, N, Oliinyk, O, Prystupa, L, Pyrogovskyi, V, Reznikova, V, Rishko, I, Stanislavchuk, M, Vizir, V, Yatsyshyn, R, Arasaradnam, R, Bloom, S, Cummings, F, Iqbal, T, Irving, P, Kaser, A, Shonde, A, Subramanian, S, Aberra, F, Aguilar, H, Araya, V, Bakken, A, Beaulieu, D, Cappa, Ja, Chiorean, M, Cohen, N, Dryden, G, Duvall, G, Ehrlich, A, Eisner, M, Ertan, A, Fogel, R, Friedenberg, K, Gatof, D, Glover, S, Grosman, I, Gunaratnam, N, Gupta, N, Haynes, P, Hemaidan, A, Higgins, P, Hou, J, Hudesman, D, Iskandar, H, Jazrawi, S, Jones, M, Karnam, U, Khurana, S, Killpack, M, Kreines, M, Lawlor, G, Lee, S, Loftus, E, Lukin, Dj, Marcet, J, Mattar, M, Melmed, G, Minor, T, Mirkin, K, Mutlu, E, Nichols, M, Nudell, J, Rai, R, Ramos, C, Mcleod, Randall, Rausher, D, Ritter, T, Singh Saini, S, Salzberg, B, Saubermann, L, Scherl, E, Sedghi, S, Sellin, J, Shafran, I, Sorrentino, D, Suiter, D, Swaminath, A, Tiongco, F, Vrabie, R, Walp, K, Warner, N, Winstead, N, Wolf, Dc, Woods, J, Yen, E, Younes, Z., Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Nutrition-Génétique et Exposition aux Risques Environnementaux (NGERE), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Humanitas Clinical and Research Center [Rozzano, Milan, Italy], RS: NUTRIM - R2 - Liver and digestive health, MUMC+: MA Maag Darm Lever (9), Interne Geneeskunde, Sands, Be, Sandborn, Wj, Panaccione, R, O'Brien, Cd, Zhang, H, Johanns, J, Adedokun, Oj, Li, K, Peyrin-Biroulet, L, Van Assche, G, Danese, S, Targan, S, Abreu, Mt, Hisamatsu, T, Szapary, P, and Marano, C
- Subjects
Adult ,Male ,Infusions ,[SDV]Life Sciences [q-bio] ,Injections, Subcutaneous ,Anti-Inflammatory Agents ,Ulcerative ,Klinikai orvostudományok ,Article ,Injections ,Maintenance Chemotherapy ,Dose-Response Relationship ,03 medical and health sciences ,0302 clinical medicine ,Double-Blind Method ,INFLIXIMAB ,Colitis, Ulcerative ,Dose-Response Relationship, Drug ,Female ,Humans ,Induction Chemotherapy ,Infusions, Intravenous ,Patient Acuity ,Remission Induction ,Ustekinumab ,ComputingMilieux_MISCELLANEOUS ,ACTIVITY INDEXES ,Subcutaneous ,Orvostudományok ,General Medicine ,EFFICACY ,Colitis ,3. Good health ,INFECTIONS ,030220 oncology & carcinogenesis ,030211 gastroenterology & hepatology ,Drug ,Intravenous - Abstract
The efficacy of ustekinumab, an antagonist of the p40 subunit of interleukin-12 and interleukin-23, as induction and maintenance therapy in patients with ulcerative colitis is unknown.We evaluated ustekinumab as 8-week induction therapy and 44-week maintenance therapy in patients with moderate-to-severe ulcerative colitis. A total of 961 patients were randomly assigned to receive an intravenous induction dose of ustekinumab (either 130 mg [320 patients] or a weight-range-based dose that approximated 6 mg per kilogram of body weight [322]) or placebo (319). Patients who had a response to induction therapy 8 weeks after administration of intravenous ustekinumab were randomly assigned again to receive subcutaneous maintenance injections of 90 mg of ustekinumab (either every 12 weeks [172 patients] or every 8 weeks [176]) or placebo (175). The primary end point in the induction trial (week 8) and the maintenance trial (week 44) was clinical remission (defined as a total score of ≤2 on the Mayo scale [range, 0 to 12, with higher scores indicating more severe disease] and no subscore1 [range, 0 to 3] on any of the four Mayo scale components).The percentage of patients who had clinical remission at week 8 among patients who received intravenous ustekinumab at a dose of 130 mg (15.6%) or 6 mg per kilogram (15.5%) was significantly higher than that among patients who received placebo (5.3%) (P0.001 for both comparisons). Among patients who had a response to induction therapy with ustekinumab and underwent a second randomization, the percentage of patients who had clinical remission at week 44 was significantly higher among patients assigned to 90 mg of subcutaneous ustekinumab every 12 weeks (38.4%) or every 8 weeks (43.8%) than among those assigned to placebo (24.0%) (P = 0.002 and P0.001, respectively). The incidence of serious adverse events with ustekinumab was similar to that with placebo. Through 52 weeks of exposure, there were two deaths (one each from acute respiratory distress syndrome and hemorrhage from esophageal varices) and seven cases of cancer (one each of prostate, colon, renal papillary, and rectal cancer and three nonmelanoma skin cancers) among 825 patients who received ustekinumab and no deaths and one case of cancer (testicular cancer) among 319 patients who received placebo.Ustekinumab was more effective than placebo for inducing and maintaining remission in patients with moderate-to-severe ulcerative colitis. (Funded by Janssen Research and Development; UNIFI ClinicalTrials.gov number, NCT02407236.).
- Published
- 2019
7. Efficacy and safety of sarilumab in combination with methotrexate in patients with active rheumatoid arthritis and inadequate effect of methotrexate monotherapy (results of phase III MOBILITY study)
- Author
-
Nasonov, E. L., primary, Stanislav, M. L., additional, Raskina, T. A., additional, Kuropatkin, G. V., additional, Shirinsky, I. V., additional, Rebrov, A. P., additional, Shostak, N. A., additional, Alikhanov, B. A., additional, Ushakov, E. N., additional, Kamalova, R. G., additional, Smakotina, S. A., additional, Simanenkov, V. I., additional, Pavsun, A. S., additional, Zaharjan, I. I., additional, Yakushin, S. S., additional, and Sandin, M. Yu., additional
- Published
- 2019
- Full Text
- View/download PDF
8. THE EFFICACY AND SAFETY OF CARMOLIS GEL IN THE COMBINATION THERAPY OF KNEE OSTEOARTHRITIS: RESULTS OF A MULTICENTER CLINICAL TRIAL
- Author
-
Denisov, I. N., primary, Zborovskaya, I. A., additional, Zavodovsky, B. V., additional, Alikhanov, B. A., additional, Karapetyan, I. V., additional, Shalygina, V. A., additional, Budushkina, V. E., additional, Vakulenko, O. Yu., additional, Nasrullaeva, A. D., additional, Sorotskaya, V. N., additional, Leonova, E. A., additional, Mironcheva, A. I., additional, and Goryachev, D. V., additional
- Published
- 2015
- Full Text
- View/download PDF
9. [Geriatric aspects of modern plastic surgery.]
- Author
-
Alikhanov BG, Iordanishvili AK, Pavlova SG, and Yushkova ID
- Subjects
- Aged, Aging, Female, Humans, Male, Motivation, Plastic Surgery Procedures, Surgery, Plastic
- Abstract
Aging of the human body is a natural physiological process. In the last century, the main reasons for people turning to plastic surgeons were congenital and acquired deformities, as well as age-related changes in the skin of the face. Nowadays, a person's appearance has become the main factor in his success in society. The work determines the motivation of elderly and senile people to perform plastic surgeries, and also analyzes the work of clinics in performing plastic surgeries for people of older age groups. It was found that 96,4% of men and 86,9% of women in older age groups have a fairly complete understanding of plastic surgery. Among the elderly and old people, 27,7% of men and 17,2% of women have a desire to perform plastic surgery for themselves, however, women are 10,9 times more likely to go to plastic surgeons. Analysis of the plastic surgery clinics showed a steady trend of increasing the number of elderly and senile people, regardless of gender, to plastic surgeons to perform operations aimed mainly at improving the aesthetics of the face, neck and body shaping by eliminating gravitational ptosis and removing excess subcutaneous fat. deposits on the trunk. The main reason for refusal to perform the operation desired by the patient and recommended by the plastic surgeon is the lack of funds.
- Published
- 2021
10. [Determination of antibodies against cyclic citrullinated peptide in rheumatoid arthritis].
- Author
-
Kobylianskiĭ AG, Sandin MIu, Kozlova VI, Alikhanov BA, and Demkin VV
- Subjects
- Adult, Aged, Arthritis, Rheumatoid diagnosis, Enzyme-Linked Immunosorbent Assay, Female, Filaggrin Proteins, Humans, Immunoglobulin M blood, Immunoglobulin M immunology, Male, Middle Aged, Rheumatoid Factor blood, Sensitivity and Specificity, Arthritis, Rheumatoid blood, Autoantibodies blood, Intermediate Filament Proteins immunology, Peptides, Cyclic immunology
- Abstract
The ability of the synthetic peptide IMG-5, that reproduces one of the antigenic determinants of the protein filaggrin, to show antigenic activity was studied when anti-cyclic citrullinated peptide antibodies (ACCPAb) to filaggrin were found in the serum samples of patients with rheumatoid arthritis (RA). The binding of IMG-5 to ACCPAb has been shown to be specific (dose-dependent and reversible). The serum samples from patients with RA, controls, and donors show a significant difference in the interaction of the synthetic peptide with ACCPAb (p < 0.005 and p < 0.0001, respectively). The level of IgM rheumatoid factor (RF) detected in patients with RA differs greatly from that in the controls. In the patients with RA versus the controls, the specificity of ACCPAb determination was as high as 87; and the sensitivity was 40.5%. When ACCPAbs were determined using the commercial kit CCP, the specificity and sensitivity were 94 and 47.3%, respectively. The specificity of RF detection was equal to 50% and the sensitivity was 70%. The sensitivity of the test using IMG-5 is a maximum in X-ray stage IRA (69.2%) and falls in its stage III (26.7%). On the contrary, the sensitivity of the commercial kit and RF determination increases from X-ray stage I (46.2 and 53.8%, respectively) to II (66.7 and 80%). The sensitivity of the used tests in varying RA activities has demonstrated that they are most effective in patients with moderate RA activity. The concurrent detection of ACCPAb and RF increases the probability of differentiating RA from other rheumatic diseases.
- Published
- 2011
11. [Effect of T-activin and irradiation with a helium-neon laser on the status of the interleukin-2-dependent component of the proliferative response of mononuclear cells in rheumatoid arthritis].
- Author
-
Parnes EIa, Alikhanov BA, Tkomachev IuK, and Muromtsev AV
- Subjects
- Arthritis, Rheumatoid blood, Arthritis, Rheumatoid pathology, Cell Division drug effects, Cell Division radiation effects, Combined Modality Therapy, Female, Helium, Humans, Interleukin-2 radiation effects, Lymphocytes drug effects, Lymphocytes radiation effects, Male, Middle Aged, Neon, Adjuvants, Immunologic therapeutic use, Arthritis, Rheumatoid therapy, Interleukin-2 blood, Laser Therapy, Lymphocytes pathology, Peptides therapeutic use, Thymus Extracts therapeutic use
- Published
- 1995
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.